OCUL vs TECH · rev $63.7M vs P/E 65, rev $1.22B
Ocular Therapeutix Inc (OCUL) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Ocular Therapeutix Inc (OCUL) is a biotechnology company listed on US.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported OCUL revenue for 2024-12-31 was $63.7M. Net income was -$193.5M. Revenue was up 9.0% from 2023-12-31 to 2024-12-31. OCUL currently screens at market cap $1.76B.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
OCUL currently screens at market cap $1.76B. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the OCUL and TECH stock pages for the full models.
Not investment advice.